deCODE Provides Update on Growing Pipeline
Phase IIa trial of DG031, progress towards the clinic in PAOD, stroke and asthma, solid financials underpin development of novel drugs for major indications
29-Jun-2004 -
Reykjavik. deCODE genetics provided an update on its lead drug development programs and the application of its population genetics resources to the clinical development process, in connection with the company's annual analyst and investor event being held in Reykjavik.
Among the highlights to be ...
asthma
atherosclerosis
biomarkers
+14